S&P 500   4,290.45 (+0.06%)
DOW   33,420.30 (-0.26%)
QQQ   360.87 (+0.73%)
AAPL   173.46 (+1.31%)
MSFT   318.86 (+0.98%)
META   305.88 (+1.89%)
GOOGL   133.62 (+2.11%)
AMZN   129.32 (+1.73%)
TSLA   251.23 (+0.40%)
NVDA   449.35 (+3.30%)
NIO   8.80 (-2.65%)
BABA   86.31 (-0.50%)
AMD   102.51 (-0.30%)
T   14.85 (-1.13%)
F   12.27 (-1.21%)
MU   67.84 (-0.28%)
CGC   0.79 (+1.14%)
GE   109.50 (-0.95%)
DIS   81.14 (+0.11%)
AMC   7.92 (-0.88%)
PFE   33.34 (+0.51%)
PYPL   58.93 (+0.80%)
NFLX   381.00 (+0.90%)
S&P 500   4,290.45 (+0.06%)
DOW   33,420.30 (-0.26%)
QQQ   360.87 (+0.73%)
AAPL   173.46 (+1.31%)
MSFT   318.86 (+0.98%)
META   305.88 (+1.89%)
GOOGL   133.62 (+2.11%)
AMZN   129.32 (+1.73%)
TSLA   251.23 (+0.40%)
NVDA   449.35 (+3.30%)
NIO   8.80 (-2.65%)
BABA   86.31 (-0.50%)
AMD   102.51 (-0.30%)
T   14.85 (-1.13%)
F   12.27 (-1.21%)
MU   67.84 (-0.28%)
CGC   0.79 (+1.14%)
GE   109.50 (-0.95%)
DIS   81.14 (+0.11%)
AMC   7.92 (-0.88%)
PFE   33.34 (+0.51%)
PYPL   58.93 (+0.80%)
NFLX   381.00 (+0.90%)
S&P 500   4,290.45 (+0.06%)
DOW   33,420.30 (-0.26%)
QQQ   360.87 (+0.73%)
AAPL   173.46 (+1.31%)
MSFT   318.86 (+0.98%)
META   305.88 (+1.89%)
GOOGL   133.62 (+2.11%)
AMZN   129.32 (+1.73%)
TSLA   251.23 (+0.40%)
NVDA   449.35 (+3.30%)
NIO   8.80 (-2.65%)
BABA   86.31 (-0.50%)
AMD   102.51 (-0.30%)
T   14.85 (-1.13%)
F   12.27 (-1.21%)
MU   67.84 (-0.28%)
CGC   0.79 (+1.14%)
GE   109.50 (-0.95%)
DIS   81.14 (+0.11%)
AMC   7.92 (-0.88%)
PFE   33.34 (+0.51%)
PYPL   58.93 (+0.80%)
NFLX   381.00 (+0.90%)
S&P 500   4,290.45 (+0.06%)
DOW   33,420.30 (-0.26%)
QQQ   360.87 (+0.73%)
AAPL   173.46 (+1.31%)
MSFT   318.86 (+0.98%)
META   305.88 (+1.89%)
GOOGL   133.62 (+2.11%)
AMZN   129.32 (+1.73%)
TSLA   251.23 (+0.40%)
NVDA   449.35 (+3.30%)
NIO   8.80 (-2.65%)
BABA   86.31 (-0.50%)
AMD   102.51 (-0.30%)
T   14.85 (-1.13%)
F   12.27 (-1.21%)
MU   67.84 (-0.28%)
CGC   0.79 (+1.14%)
GE   109.50 (-0.95%)
DIS   81.14 (+0.11%)
AMC   7.92 (-0.88%)
PFE   33.34 (+0.51%)
PYPL   58.93 (+0.80%)
NFLX   381.00 (+0.90%)
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

$142.02
-4.02 (-2.75%)
(As of 11:09 AM ET)
Compare
Today's Range
$141.33
$146.04
50-Day Range
$146.04
$210.63
52-Week Range
$57.21
$322.67
Volume
144,997 shs
Average Volume
373,225 shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$309.18

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
117.7% Upside
$309.18 Price Target
Short Interest
Bearish
16.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.81mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($18.87) to ($12.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

93rd out of 969 stocks

Pharmaceutical Preparations Industry

29th out of 453 stocks


MDGL stock logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Price History

MDGL Stock News Headlines

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up to $151.69
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Madrigal Pharma Announces Pricing Of $500 Mln Public Offering - Quick Facts
Madrigal Pharmaceuticals Announces Proposed Public Offering
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
The Latest Analyst Ratings for Madrigal Pharmaceuticals
John Paulson's Q2 2023 13F Filing Update
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings
8/08/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
92
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$309.18
High Stock Price Forecast
$390.00
Low Stock Price Forecast
$224.00
Forecasted Upside/Downside
+111.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-295,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.54 per share

Miscellaneous

Free Float
14,053,000
Market Cap
$2.70 billion
Optionable
Optionable
Beta
-0.72

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Rebecca A. Taub M.D. (Age 71)
    Founder, Chief Medical Officer, Pres of R&D and Director
    Comp: $939.83k
  • Mr. Alex G. Howarth (Age 54)
    Sr. VP & CFO
    Comp: $757.26k
  • Mr. Brian J. Lynch J.D. (Age 61)
    Sr. VP & Gen. Counsel
    Comp: $763.75k
  • Mr. Remy Sukhija (Age 51)
    Sr. VP & Chief Commercial Officer
    Comp: $785.2k
  • Mr. William J. Sibold (Age 57)
    CEO & Director
  • Dr. Kianoush Motesharei Ph.d. (Age 53)
    Sr. VP of Bus. & Corp. Devel.
  • Mr. Edward Chiang
    Sr. VP of Clinical & Technical Operations
  • Mr. Thomas W. Hare
    Sr. VP of Clinical Management
  • Dr. Robert E. Waltermire Ph.D. (Age 59)
    Chief Pharmaceutical Devel. Officer
  • Dr. Stephen Dodge M.B.A.
    Pharm.D., Sr. VP of Global Medical Affairs













MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2023?

11 equities research analysts have issued 12 month target prices for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $224.00 to $390.00. On average, they anticipate the company's stock price to reach $309.18 in the next year. This suggests a possible upside of 111.7% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2023?

Madrigal Pharmaceuticals' stock was trading at $290.25 on January 1st, 2023. Since then, MDGL stock has decreased by 49.7% and is now trading at $146.04.
View the best growth stocks for 2023 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($4.69) EPS for the quarter, missing analysts' consensus estimates of ($4.59) by $0.10.

What ETFs hold Madrigal Pharmaceuticals' stock?
What other stocks do shareholders of Madrigal Pharmaceuticals own?
What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $146.04.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $2.70 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.65) on an earnings per share basis.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -